Early Feasibility Study: Application of OCT Imaging in Dermatology
1 other identifier
observational
123
1 country
1
Brief Summary
Optical coherence tomography (OCT) is an established medical imaging technique that uses light to capture biological images from within optical scattering media (e.g., biological tissue). A high-resolution OCT has the characteristics of non-invasive, label-free, real-time, cellular resolution with high tissue penetration depth that are highly valuable for clinical use. AMO has developed an in-vivo OCT scanning system prototype based on the clinical needs and potential applications. This study is designed as an early feasibility study aiming for validation of AMO's in-vivo OCT scanning system in dermatology through collaboration with Mackay Memorial Hospital. The OCT can provide cellular-resolution (\<1μm in lateral and axial directions) images which can be utilized to identify organelles. A high-resolution OCT has the characteristics of non-invasive, label-free, real-time, cellular resolution with high tissue penetration depth that are highly valuable for clinical use. The proposed scenario in this study is to collecting OCT images of skins with suspicious lesion including tumor, inflammatory diseases or pigment alteration as well as normal skin by using AMO's in vivo OCT imaging system. By using traditional pathological biopsy images or dermoscopic images as gold standard references, investigators will try to identify different characteristics in OCT images of skin with suspicious lesion including tumor, inflammatory diseases, or pigment alteration as well as normal skins.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Jan 2018
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 29, 2018
CompletedFirst Submitted
Initial submission to the registry
August 19, 2019
CompletedFirst Posted
Study publicly available on registry
August 26, 2019
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 2, 2019
CompletedStudy Completion
Last participant's last visit for all outcomes
October 2, 2019
CompletedApril 22, 2021
April 1, 2021
1.7 years
August 19, 2019
April 21, 2021
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
Number of subjects with clear tissue characteristics of skin diseases and/or normal skin in tomograms
Number of subjects with clear tissue characteristics of tomograms will be compared to that with unclear tissue characteristics to identify the effect of the OCT on scanning skin at study completion.
2 years
Number of subjects with the distinction between skin lesion and normal skin in tomograms
Number of subjects with the distinction between skin lesion and normal skin in tomograms will be compared to that with no distinction to verify the specific diseases that can be distinguished from others by the OCT at study completion.
2 years
Secondary Outcomes (2)
Number of subjects with clear tissue stratification of skin diseases and/or normal skin in tomograms
2 years
Number of subjects with the similarity of tissue characteristics, tissue stratification, and tissue thickness between tomograms and H&E stain
2 years
Study Arms (1)
Experimental
Suspected skin inflammations or skin tumors
Interventions
The device is an in vivo non-invasive optical coherence tomography and will be used to obtain at least 6 medical images of normal and lesional skin, respectively, for experimental group.
Eligibility Criteria
The population from experimental group will be selected.
You may qualify if:
- A patient who is fully aware of the trial and can sign the inform consent form himself/herself
- Patients with suspected skin tumors or skin inflammations
- Patients diagnosed for biopsy
- Patients with no open wounds in the tumor or inflamed position
You may not qualify if:
- Patients with a transcutaneous infectious disease
- Patients under the age of 20
- Vulnerable populations, including: pregnant women, handicapped, and homelessness
- Patient cannot cooperate in examination
- Patients with skin tumors that are in the subcutaneous tissue
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Mackay Memorial Hospitallead
- Apollo Medical Optics, Ltdcollaborator
Study Sites (1)
Mackay Memorial Hospital
New Taipei City, Tamsui District, 25160, Taiwan
Related Publications (8)
Chang CK, Tsai CC, Hsu WY, Chen JS, Liao YH, Sheen YS, Hong JB, Lin MY, Tjiu JW, Huang SL. Errata: Segmentation of nucleus and cytoplasm of a single cell in three-dimensional tomogram using optical coherence tomography. J Biomed Opt. 2017 Mar 1;22(3):39801. doi: 10.1117/1.JBO.22.3.039801. No abstract available.
PMID: 28300273BACKGROUNDChiu YK, Chen WL, Tsai CT, Yang CH, and Huang SL. A high en-face resolution AS-OCT providing quantitative ability to measure layered corneal opacities. European Conferences on Biomedical Optics, Munich Germany, 25-29, 2017.
BACKGROUNDWang SC, Hsu CY, Yang TT, Jheng DY, Yang TI, Ho TS, Huang SL. Laser-diode pumped glass-clad Ti:sapphire crystal fiber laser. Opt Lett. 2016 Jul 15;41(14):3217-20. doi: 10.1364/OL.41.003217.
PMID: 27420499BACKGROUNDWang SC, Yang TI, Jheng DY, Hsu CY, Yang TT, Ho TS, Huang SL. Broadband and high-brightness light source: glass-clad Ti:sapphire crystal fiber. Opt Lett. 2015 Dec 1;40(23):5594-7. doi: 10.1364/OL.40.005594.
PMID: 26625059BACKGROUNDTsai CC, Chang CK, Hsu KY, Ho TS, Lin MY, Tjiu JW, Huang SL. Full-depth epidermis tomography using a Mirau-based full-field optical coherence tomography. Biomed Opt Express. 2014 Aug 8;5(9):3001-10. doi: 10.1364/BOE.5.003001. eCollection 2014 Sep 1.
PMID: 25401013BACKGROUNDHo TS, Yeh P, Tsai CC, Hsu KY, Huang SL. Spectroscopic measurement of absorptive thin films by spectral-domain optical coherence tomography. Opt Express. 2014 Mar 10;22(5):5675-83. doi: 10.1364/OE.22.005675.
PMID: 24663908BACKGROUNDCheng NC, Hsieh TH, Wang YT, Lai CC, Chang CK, Lin MY, Huang DW, Tjiu JW, Huang SL. Cell death detection by quantitative three-dimensional single-cell tomography. Biomed Opt Express. 2012 Sep 1;3(9):2111-20. doi: 10.1364/BOE.3.002111. Epub 2012 Aug 13.
PMID: 23024905BACKGROUNDWang YJ, Huang YK, Wang JY, Wu YH. In vivo characterization of large cell acanthoma by cellular resolution optical coherent tomography. Photodiagnosis Photodyn Ther. 2019 Jun;26:199-202. doi: 10.1016/j.pdpdt.2019.03.020. Epub 2019 Mar 30. No abstract available.
PMID: 30940575RESULT
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Yen-Jen Wang, MD
Mackay Memorial Hospital
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
August 19, 2019
First Posted
August 26, 2019
Study Start
January 29, 2018
Primary Completion
October 2, 2019
Study Completion
October 2, 2019
Last Updated
April 22, 2021
Record last verified: 2021-04